Search

1 to 10 of 18
Sort by

Library Entry
Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit

Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining...



Library Entry
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell...


Library Entry
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art

Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomarker development and utilization, the Society for Immunotherapy of Cancer (SITC) convened...


Library Entry
SITC 2018 Year in Review

Available here is the Society for Immunotherapy of Cancer (SITC) 2018 Year in Review. Highlighted in the review are the multiple programs and initiatives made during 2018 as well as a look forward to 2019. #Document #SITCPublication #SITC #2018

SITC 2018 Year in Review.pdf


Library Entry
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients with...



Library Entry
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here the authors present their consensus recommendations on managing toxicities...


Library Entry
SITC 2017 Accomplishments Report

Available here is the Society for Immunotherapy of Cancer (SITC) 2017 Accomplishments Report. SITC is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. A 501(c)(3) not-for-profit organization, SITC...

SITC 2017 Accomplishments Report.pdf


Library Entry
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy

The Society for Immunotherapy of Cancer (SITC) convened a workshop titled, “Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy” as part of the SITC 31st Annual Meeting and Associated Programs on November 10, 2016 in National Harbor,...